GLUE
Monte Rosa Therapeutics, Inc.NASDAQHealthcare$17.09-0.47%ClosedMarket Cap: $1.11B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.76
P/S
8.91
EV/EBITDA
-23.46
DCF Value
$23.91
FCF Yield
-2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.6%
Operating Margin
-43.8%
Net Margin
-31.2%
ROE
-15.1%
ROA
-8.6%
ROIC
-13.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.8M | 24.9% | $-49.7M | $-46.1M | $-0.70 | — |
| FY 2025 | $123.7M | 93.2% | $-54.2M | $-38.6M | $-0.46 | — |
| Q3 2025 | $12.8M | 83.6% | $-33.0M | $-27.1M | $-0.33 | — |
| Q2 2025 | $23.2M | 100.0% | $-15.6M | $-12.3M | $-0.15 | — |
| Q1 2025 | $84.9M | 100.0% | $44.0M | $46.9M | $0.57 | — |
| Q4 2024 | $60.6M | 100.0% | $13.0M | $13.4M | $0.22 | — |
| FY 2024 | $75.6M | 89.3% | $-81.1M | $-72.7M | $-0.98 | — |
| Q3 2024 | $9.2M | 100.0% | $-26.5M | $-23.9M | $-0.29 | — |
| Q2 2024 | $4.7M | 56.1% | $-32.6M | $-30.3M | $-0.43 | — |
| Q1 2024 | $1.1M | -78.3% | $-34.9M | $-32.0M | $-0.53 | — |
| Q4 2023 | $0.00 | NaN% | $-34.9M | $-33.3M | $-0.58 | — |
| FY 2023 | $0.00 | -Infinity% | $-143.3M | $-135.4M | $-2.63 | — |